Key Takeaways
- FDA flagged Empower Pharmacy for compounding semaglutide and tirzepatide outside qualified exemptions.
- Inspectors found insanitary sterile-drug conditions and poor aseptic data practices at the facility.
- The compounded GLP-1s resemble FDA-approved versions, raising questions about their legality and patient safety.
- Patients should know compounded GLP-1s carry risks that differ from FDA-approved treatments.
What did the Empower Pharmacy warning say?
The FDA cited Empower Clinic Services, LLC (dba Empower Pharmacy) in Houston on September 18, 2026, for compounding semaglutide and tirzepatide under conditions that violated section 503A of the FD&C Act. Inspectors found the facility produced “essentially copies” of FDA-approved GLP-1 drugs regularly and in large volume, with B-vitamins added as a superficial difference. The agency documented insanitary conditions in the sterile compounding area and lapses in good manufacturing practice: weak smoke studies, flawed media-fill records, and transcription gaps in sterility data (fda.gov).
Why does FDA say this matters for compounded GLP-1s?
Compounded drugs must meet strict conditions. Under section 503A, pharmacies may compound only for individual patients with documented, patient-specific need. At Empower, inspectors found prescriber notes that appeared repeated verbatim, not tailored to each patient. High-volume compounding of these GLP-1s without unique medical justification disqualifies them from exemptions and subjects them to FDA approval, labeling, and CGMP requirements—none of which were met (fda.gov).
Could patients be at risk from these compounded GLP-1s?
Yes. Compounded semaglutide and tirzepatide escape rigorous FDA review for safety, effectiveness, and quality. The agency has logged nearly 1,000 adverse events tied to compounded semaglutide and over 730 linked to compounded tirzepatide as of May 31, 2026. Problems include dosing errors, unapproved salt forms, and mislabeled or fraudulent products. Insanitary compounding adds infection and contamination risks on top of dosing and labeling issues (fda.gov).
What’s the next step for Empower and for patients?
The FDA demands that Empower Pharmacy respond within 15 working days with specific corrective steps and documentation. Without adequate action, the FDA may seek seizure or injunction against the firm under the FD&C Act (fda.gov). Patients using or considering compounded GLP-1s should consult their doctor, seek FDA-approved alternatives, and report any concerns to their healthcare provider.
FAQ
What is the Empower Pharmacy warning about?
The FDA issued a warning letter on September 18, 2026, citing insanitary compounding conditions and mass production of semaglutide and tirzepatide that mirror FDA-approved drugs without approval or patient-specific justification.
Why did the FDA target Empower Pharmacy?
FDA investigators found Empower compounded GLP-1 products—semaglutide and tirzepatide—regularly in high volume with superficial modifications, under insanitary conditions, violating section 503A compounding rules.
Are compounded GLP-1 drugs safe?
Compounded GLP-1s lack FDA review for safety, quality, and effectiveness. The FDA has recorded hundreds of adverse events including dosing errors and contamination issues tied to compounded semaglutide and tirzepatide.
What should patients using GLP-1s do now?
Patients should stick with FDA-approved GLP-1 medications, talk with their healthcare provider before using compounded versions, and verify their source is state-licensed and follows compounding laws.
Can Empower continue compounding GLP-1s legally?
The letter calls for corrective action and warns of possible enforcement. It does not itself determine the legality of every future prescription; that depends on compliance with the applicable requirements.
This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision—talk to a licensed healthcare provider before starting, stopping, or changing any treatment.